| Literature DB >> 29629902 |
Hania Kebir1,2, Lionel Carmant3,4,5, François Fontaine3,4, Kathie Béland3, Ciprian M Bosoi3, Nathalie T Sanon3, Jorge I Alvarez6, Sébastien Desgent3, Camille L Pittet2, David Hébert3, Marie-Josée Langlois3, Rose-Marie Rébillard4, Dang K Nguyen2,5, Cécile Cieuta-Walti7, Gregory L Holmes8, Howard P Goodkin9, John R Mytinger9, Mary B Connolly10, Alexandre Prat2,5, Elie Haddad1,3,4.
Abstract
Rasmussen's encephalitis (RE) is a chronic inflammatory brain disorder that causes frequent seizures and unilateral hemispheric atrophy with progressive neurological deficits. Hemispherectomy remains the only treatment that leads to seizure freedom for this refractory epileptic syndrome. The absence of an animal model of disease has been a major obstacle hampering the development of effective therapies. Here, we describe an experimental mouse model that shares several clinical and pathological features with the human disease. Immunodeficient mice injected with peripheral blood mononuclear cells from RE patients and monitored by video electroencephalography developed severe seizures of cortical origin and showed intense astrogliosis and accumulation of human IFN-γ- and granzyme B-expressing T lymphocytes in the brain compared with mice injected with immune cells from control subjects. We also provide evidence for the efficacy of α4 integrin blockade, an approved therapy for the treatment of multiple sclerosis and Crohn's disease, in reducing inflammatory markers associated with RE in the CNS. This model holds promise as a valuable tool for understanding the pathology of RE and for developing patient-tailored experimental therapeutics.Entities:
Keywords: Immunology; Immunotherapy; Mouse models; Neurological disorders; Neuroscience
Mesh:
Year: 2018 PMID: 29629902 PMCID: PMC5919802 DOI: 10.1172/JCI97098
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808